Adenosine Deaminases Acting on RNA Downregulate the Expression of Constitutive Androstane Receptor in the Human Liver-Derived Cells by Attenuating Splicing
Adenosine deaminases acting on RNA (ADARs) enzymes-catalyzing adenosine-to-inosine RNA editing possibly modulates gene expression and function. In this study, we investigated whether ADARs regulate the expression of human constitutive androstane receptor (CAR), which controls the expression of vario...
Saved in:
Published in | The Journal of pharmacology and experimental therapeutics Vol. 370; no. 3; pp. 408 - 415 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
United States
01.09.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Adenosine deaminases acting on RNA (ADARs) enzymes-catalyzing adenosine-to-inosine RNA editing possibly modulates gene expression and function. In this study, we investigated whether ADARs regulate the expression of human constitutive androstane receptor (CAR), which controls the expression of various drug-metabolizing enzymes. CAR mRNA and protein levels in human hepatocellular carcinoma-derived HepG2 cells were increased by knockdown of ADAR1 and slightly increased by ADAR2, indicating that ADARs negatively regulate CAR expression. Increased luciferase activity of a reporter plasmid containing the CYP3A4 promoter region by phenobarbital was augmented by transfection of siRNA for ADAR1 (siADAR1) but not by siADAR2. In addition, the knockdown of ADAR1 resulted in the enhanced induction of CYP2B6 and CYP3A4 mRNA by 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde
-(3,4-dichlorobenzyl)oxime and phenobarbital, respectively. These results suggest that ADAR1-mediated downregulation of CAR affects its downstream cytochrome P450 expression. When the transcription was inhibited by
-amanitin, the degradation of CAR mRNA was attenuated by knockdown of ADAR1, suggesting that the increase in CAR mRNA level by ADAR1 knockdown is a post-transcriptional event. Finally, we found that ADAR1 knockdown promotes the splicing of CAR as a mechanism of the increased expression of CAR by ADAR1 knockdown. In conclusion, this study revealed that ADAR1 plays a role in modulating xenobiotic metabolism potency via regulation of CAR. SIGNIFICANCE STATEMENT: This study revealed that adenosine deaminase acting on RNA 1 (ADAR1) and ADAR2, which catalyze adenosine-to-inosine RNA editing, downregulate the expression of constitutive androstane receptor (CAR) in human liver-derived cells by attenuating splicing. The downregulation of CAR by ADARs affected its downstream cytochrome P450 expression. ADARs would play a role in modulating xenobiotic metabolism potency via regulation of CAR. |
---|---|
AbstractList | Adenosine deaminases acting on RNA (ADARs) enzymes-catalyzing adenosine-to-inosine RNA editing possibly modulates gene expression and function. In this study, we investigated whether ADARs regulate the expression of human constitutive androstane receptor (CAR), which controls the expression of various drug-metabolizing enzymes. CAR mRNA and protein levels in human hepatocellular carcinoma-derived HepG2 cells were increased by knockdown of ADAR1 and slightly increased by ADAR2, indicating that ADARs negatively regulate CAR expression. Increased luciferase activity of a reporter plasmid containing the CYP3A4 promoter region by phenobarbital was augmented by transfection of siRNA for ADAR1 (siADAR1) but not by siADAR2. In addition, the knockdown of ADAR1 resulted in the enhanced induction of CYP2B6 and CYP3A4 mRNA by 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde
-(3,4-dichlorobenzyl)oxime and phenobarbital, respectively. These results suggest that ADAR1-mediated downregulation of CAR affects its downstream cytochrome P450 expression. When the transcription was inhibited by
-amanitin, the degradation of CAR mRNA was attenuated by knockdown of ADAR1, suggesting that the increase in CAR mRNA level by ADAR1 knockdown is a post-transcriptional event. Finally, we found that ADAR1 knockdown promotes the splicing of CAR as a mechanism of the increased expression of CAR by ADAR1 knockdown. In conclusion, this study revealed that ADAR1 plays a role in modulating xenobiotic metabolism potency via regulation of CAR. SIGNIFICANCE STATEMENT: This study revealed that adenosine deaminase acting on RNA 1 (ADAR1) and ADAR2, which catalyze adenosine-to-inosine RNA editing, downregulate the expression of constitutive androstane receptor (CAR) in human liver-derived cells by attenuating splicing. The downregulation of CAR by ADARs affected its downstream cytochrome P450 expression. ADARs would play a role in modulating xenobiotic metabolism potency via regulation of CAR. |
Author | Nakano, Masataka Nakajima, Miki Fukami, Tatsuki |
Author_xml | – sequence: 1 givenname: Masataka surname: Nakano fullname: Nakano, Masataka organization: Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences and WPI Nano Life Science Institute, Kanazawa University, Kakuma-machi, Kanazawa, Japan – sequence: 2 givenname: Tatsuki surname: Fukami fullname: Fukami, Tatsuki organization: Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences and WPI Nano Life Science Institute, Kanazawa University, Kakuma-machi, Kanazawa, Japan – sequence: 3 givenname: Miki surname: Nakajima fullname: Nakajima, Miki email: nmiki@p.kanazawa-u.ac.jp organization: Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences and WPI Nano Life Science Institute, Kanazawa University, Kakuma-machi, Kanazawa, Japan nmiki@p.kanazawa-u.ac.jp |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31270214$$D View this record in MEDLINE/PubMed |
BookMark | eNo9kMtOwzAQRS1URB-wZof8A2n9yENeRm2hSBVIBdaR40yKq9SJbAfot_CzuC2wmivNvXdGZ4wGpjWA0C0lU0pZPNt14IMSU5YSSsQFGtGE0ShoPkAjQhiLeJImQzR2bkcIjeOUX6EhpywjjMYj9J1XYFqnDeAFyL020oHDufLabHFr8OYpx4v201jY9o30gP074OVXZ8E5HfZtjeetcV773usPwLmpbOu8DH0bUND51mJtTqlVv5cGr4PLRguwYVZ4Dk3jcHnAufdgenk6-9I1WgVxjS5r2Ti4-Z0T9Ha_fJ2vovXzw-M8X0cqJrGP6jpjLEniKoMqS1NOVckVVLJOFS9VJlMuIJNxSUXFQYAUtUgSUgIIRViSUT5Bs3OvCq87C3XRWb2X9lBQUhwxF0fMQYnijDkk7s6Jri_3UP37_7jyHyaRfpw |
CitedBy_id | crossref_primary_10_1124_dmd_121_000390 crossref_primary_10_3390_cells9112395 crossref_primary_10_1016_j_bcp_2019_113697 crossref_primary_10_1124_dmd_123_001396 crossref_primary_10_1021_acsami_2c19285 crossref_primary_10_1016_j_dmpk_2020_11_002 |
Cites_doi | 10.1016/S0928-0987(00)00112-3 10.1016/j.bcp.2010.02.023 10.1073/pnas.91.24.11457 10.1016/j.febslet.2007.11.011 10.1002/hep.21671 10.1074/jbc.M709382200 10.1124/mol.54.6.1113 10.1016/j.pharmthera.2017.07.003 10.1074/jbc.M109.016808 10.1080/03602530600569828 10.1016/j.jhep.2010.10.029 10.1124/pr.58.4.6 10.1038/nrm.2015.4 10.1124/dmd.119.086702 10.1002/bies.201700188 10.1038/nbt.2122 10.1093/nar/gkw767 10.1073/pnas.0909731106 10.1136/gut.2006.093260 10.4161/rna.7.2.11568 10.1016/j.tibs.2008.06.001 10.1074/jbc.TM118.004166 10.1097/00008571-200007000-00001 10.1158/0008-5472.CAN-04-0166 10.1016/j.apsb.2016.07.016 10.1074/jbc.M115.699363 10.1080/15476286.2016.1203501 10.1038/nsmb.3403 10.1186/gm508 10.2133/dmpk.19.103 10.1074/jbc.M310068200 10.1210/me.2002-0244 10.1074/jbc.RA117.001197 10.1006/abbi.2001.2499 10.1074/jbc.M600931200 |
ContentType | Journal Article |
Copyright | Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics. |
Copyright_xml | – notice: Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1124/jpet.119.260109 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1521-0103 |
EndPage | 415 |
ExternalDocumentID | 10_1124_jpet_119_260109 31270214 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -~X .55 .GJ 0R~ 18M 2WC 3O- 4.4 53G 5GY 5RE 5VS 8WZ A6W AAJMC AAYOK ABCQX ABIVO ABJNI ABOCM ABSQV ACGFO ACGFS ACNCT ADBBV ADCOW ADIYS AENEX AERNN AFFNX AFHIN AFOSN AGFXO AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P F9R GX1 H13 HZ~ INIJC KQ8 L7B LSO MJL MVM NPM O9- OHT OK1 P2P R.V R0Z RHF RHI RPT TR2 UQL VH1 W2D W8F WH7 WOQ X7M YBU YHG YQT ZGI ZXP AAYXX CITATION |
ID | FETCH-LOGICAL-c404t-ff722554d7ed76631cb3cedaf6c3bc7a639e7a4b19d3e9ea9f9550bee9c025713 |
ISSN | 0022-3565 |
IngestDate | Thu Sep 26 19:43:31 EDT 2024 Sat Sep 28 08:32:24 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
License | Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c404t-ff722554d7ed76631cb3cedaf6c3bc7a639e7a4b19d3e9ea9f9550bee9c025713 |
OpenAccessLink | https://jpet.aspetjournals.org/content/jpet/370/3/408.full.pdf |
PMID | 31270214 |
PageCount | 8 |
ParticipantIDs | crossref_primary_10_1124_jpet_119_260109 pubmed_primary_31270214 |
PublicationCentury | 2000 |
PublicationDate | 2019-09-01 |
PublicationDateYYYYMMDD | 2019-09-01 |
PublicationDate_xml | – month: 09 year: 2019 text: 2019-09-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The Journal of pharmacology and experimental therapeutics |
PublicationTitleAlternate | J Pharmacol Exp Ther |
PublicationYear | 2019 |
References | 2019081415070058000_370.3.408.19 2019081415070058000_370.3.408.18 2019081415070058000_370.3.408.14 2019081415070058000_370.3.408.36 2019081415070058000_370.3.408.17 2019081415070058000_370.3.408.16 Gerber (2019081415070058000_370.3.408.9) 1997; 3 2019081415070058000_370.3.408.22 2019081415070058000_370.3.408.21 2019081415070058000_370.3.408.24 2019081415070058000_370.3.408.23 Nakano (2019081415070058000_370.3.408.15) 2018; 181 2019081415070058000_370.3.408.20 Hedrich (2019081415070058000_370.3.408.10) 2016; 6 2019081415070058000_370.3.408.29 2019081415070058000_370.3.408.26 2019081415070058000_370.3.408.25 2019081415070058000_370.3.408.28 2019081415070058000_370.3.408.27 2019081415070058000_370.3.408.1 2019081415070058000_370.3.408.3 2019081415070058000_370.3.408.4 2019081415070058000_370.3.408.11 2019081415070058000_370.3.408.33 2019081415070058000_370.3.408.32 2019081415070058000_370.3.408.13 2019081415070058000_370.3.408.35 2019081415070058000_370.3.408.12 2019081415070058000_370.3.408.34 Ben-Shoshan (2019081415070058000_370.3.408.2) 2017; 14 2019081415070058000_370.3.408.5 2019081415070058000_370.3.408.6 2019081415070058000_370.3.408.7 2019081415070058000_370.3.408.31 2019081415070058000_370.3.408.8 2019081415070058000_370.3.408.30 |
References_xml | – ident: 2019081415070058000_370.3.408.16 doi: 10.1016/S0928-0987(00)00112-3 – ident: 2019081415070058000_370.3.408.25 doi: 10.1016/j.bcp.2010.02.023 – ident: 2019081415070058000_370.3.408.11 doi: 10.1073/pnas.91.24.11457 – ident: 2019081415070058000_370.3.408.35 doi: 10.1016/j.febslet.2007.11.011 – ident: 2019081415070058000_370.3.408.21 doi: 10.1002/hep.21671 – ident: 2019081415070058000_370.3.408.32 doi: 10.1074/jbc.M709382200 – ident: 2019081415070058000_370.3.408.29 doi: 10.1124/mol.54.6.1113 – volume: 181 start-page: 13 year: 2018 ident: 2019081415070058000_370.3.408.15 article-title: Significance of A-to-I RNA editing of transcripts modulating pharmacokinetics and pharmacodynamics publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2017.07.003 contributor: fullname: Nakano – ident: 2019081415070058000_370.3.408.8 doi: 10.1074/jbc.M109.016808 – ident: 2019081415070058000_370.3.408.3 doi: 10.1080/03602530600569828 – ident: 2019081415070058000_370.3.408.28 doi: 10.1016/j.jhep.2010.10.029 – ident: 2019081415070058000_370.3.408.13 doi: 10.1124/pr.58.4.6 – ident: 2019081415070058000_370.3.408.17 doi: 10.1038/nrm.2015.4 – ident: 2019081415070058000_370.3.408.18 doi: 10.1124/dmd.119.086702 – ident: 2019081415070058000_370.3.408.34 doi: 10.1002/bies.201700188 – ident: 2019081415070058000_370.3.408.22 doi: 10.1038/nbt.2122 – ident: 2019081415070058000_370.3.408.23 doi: 10.1093/nar/gkw767 – ident: 2019081415070058000_370.3.408.7 doi: 10.1073/pnas.0909731106 – ident: 2019081415070058000_370.3.408.36 doi: 10.1136/gut.2006.093260 – ident: 2019081415070058000_370.3.408.1 doi: 10.4161/rna.7.2.11568 – ident: 2019081415070058000_370.3.408.12 doi: 10.1016/j.tibs.2008.06.001 – volume: 3 start-page: 453 year: 1997 ident: 2019081415070058000_370.3.408.9 article-title: Two forms of human double-stranded RNA-specific editase 1 (hRED1) generated by the insertion of an Alu cassette publication-title: RNA contributor: fullname: Gerber – ident: 2019081415070058000_370.3.408.27 doi: 10.1074/jbc.TM118.004166 – ident: 2019081415070058000_370.3.408.19 doi: 10.1097/00008571-200007000-00001 – ident: 2019081415070058000_370.3.408.33 doi: 10.1158/0008-5472.CAN-04-0166 – volume: 6 start-page: 413 year: 2016 ident: 2019081415070058000_370.3.408.10 article-title: Insights into CYP2B6-mediated drug-drug interactions publication-title: Acta Pharm Sin B doi: 10.1016/j.apsb.2016.07.016 contributor: fullname: Hedrich – ident: 2019081415070058000_370.3.408.14 doi: 10.1074/jbc.M115.699363 – volume: 14 start-page: 587 year: 2017 ident: 2019081415070058000_370.3.408.2 article-title: ADAR1 deletion induces NFκB and interferon signaling dependent liver inflammation and fibrosis publication-title: RNA Biol doi: 10.1080/15476286.2016.1203501 contributor: fullname: Ben-Shoshan – ident: 2019081415070058000_370.3.408.26 doi: 10.1038/nsmb.3403 – ident: 2019081415070058000_370.3.408.30 doi: 10.1186/gm508 – ident: 2019081415070058000_370.3.408.31 doi: 10.2133/dmpk.19.103 – ident: 2019081415070058000_370.3.408.5 doi: 10.1074/jbc.M310068200 – ident: 2019081415070058000_370.3.408.20 doi: 10.1210/me.2002-0244 – ident: 2019081415070058000_370.3.408.4 doi: 10.1074/jbc.RA117.001197 – ident: 2019081415070058000_370.3.408.24 doi: 10.1006/abbi.2001.2499 – ident: 2019081415070058000_370.3.408.6 doi: 10.1074/jbc.M600931200 |
SSID | ssj0014463 |
Score | 2.3820572 |
Snippet | Adenosine deaminases acting on RNA (ADARs) enzymes-catalyzing adenosine-to-inosine RNA editing possibly modulates gene expression and function. In this study,... |
SourceID | crossref pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 408 |
SubjectTerms | Adenosine Deaminase - deficiency Adenosine Deaminase - genetics Adenosine Deaminase - metabolism Biocatalysis Cytochrome P-450 CYP2B6 - biosynthesis Cytochrome P-450 CYP3A - biosynthesis Down-Regulation Enzyme Induction Gene Knockdown Techniques Hep G2 Cells Humans Liver - cytology Receptors, Cytoplasmic and Nuclear - genetics RNA Splicing RNA Stability RNA-Binding Proteins - genetics RNA-Binding Proteins - metabolism |
Title | Adenosine Deaminases Acting on RNA Downregulate the Expression of Constitutive Androstane Receptor in the Human Liver-Derived Cells by Attenuating Splicing |
URI | https://www.ncbi.nlm.nih.gov/pubmed/31270214 |
Volume | 370 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLXKkNBeEONrA4buA5qQuowldpPmMdoGE4JqQp3Ut8pxHKnrllYkBcZf4T_wG3evnQ93GhLwEqVOnCg9R_axfXwvY29QcWAvKQIv1IOhR_FKPJmq0FNBzv1MCBwIGYPsKDw9Fx8ng0mv99txLa2q9ED9vHNfyf-gimWIK-2S_Qdk24diAZ4jvnhEhPH4VxgnGYX6Jp14rCV5Wkpd9hNlncxF_8soQYH8HSubfPPaiMyTH7X11ehEytdpzAJkICJz44LUIuVyILuL8aqbWnau_xOZOLxj_LRvZmL48rIk-ZpUKLwpZDgF96b18KY7vOio6AjfZRct2wZ_Wssy4GwIa-X-SM6lSRHe_yxLWeGvlnarOX64IZ2sytV85la5mF1JuzWgLq9nN_zOvoWdU90iBzTfccjdJpvbZCM1N7nTAAsTJeKOjiEQ1DHgSATP4wMKpGbCMlQOTZZXhiecFuMDu7X1Vizu5tI9dj_Aho1a1A-T1lJEQ2teh4_C97279bZN9qCpvyaC1oYzRtaMH7GHNSyQWHJtsZ4uHrO9MwvR9T6MHTj2YQ_OHPCesF8tA6FjIFgGwqIAZCC4DAREFzoGwiIHl4HQMRAaBsKsMLUMA2GNgWAYCOk1OAyEhoFP2fn7k_HRqVen-_CUOBSVl-cRdi4DkUU6i1AI-yrlSmcyDxVPVSRRS-tIitSPM65jLeM8xuF1qnWsULhHPn_GNopFobcZDIXCm1Qm4kwhJtEww5aI1oBDzeUw4DvsbfP_T5c2qsvUjIYDMSXU8CyeWtR22HOLT3tjA-KLP155yTY7Lr9iG9XXld5F7Vqlrw1hbgBh5aHC |
link.rule.ids | 315,783,787,27936,27937 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adenosine+Deaminases+Acting+on+RNA+Downregulate+the+Expression+of+Constitutive+Androstane+Receptor+in+the+Human+Liver-Derived+Cells+by+Attenuating+Splicing&rft.jtitle=The+Journal+of+pharmacology+and+experimental+therapeutics&rft.au=Nakano%2C+Masataka&rft.au=Fukami%2C+Tatsuki&rft.au=Nakajima%2C+Miki&rft.date=2019-09-01&rft.eissn=1521-0103&rft.volume=370&rft.issue=3&rft.spage=408&rft_id=info:doi/10.1124%2Fjpet.119.260109&rft_id=info%3Apmid%2F31270214&rft.externalDocID=31270214 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3565&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3565&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3565&client=summon |